- Home
- LNZA vs SERA Comparison
LNZA vs SERA Comparison
Compare LNZA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- SERA
- Stock Information
- Founded
- LNZA 2005
- SERA 2008
- Country
- LNZA United States
- SERA United States
- Employees
- LNZA N/A
- SERA N/A
- Industry
- LNZA Major Chemicals
- SERA Precision Instruments
- Sector
- LNZA Industrials
- SERA Health Care
- Exchange
- LNZA Nasdaq
- SERA Nasdaq
- Market Cap
- LNZA 65.7M
- SERA 70.4M
- IPO Year
- LNZA N/A
- SERA 2021
- Fundamental
- Price
- LNZA $0.29
- SERA $2.92
- Analyst Decision
- LNZA Hold
- SERA
- Analyst Count
- LNZA 2
- SERA 0
- Target Price
- LNZA $2.00
- SERA N/A
- AVG Volume (30 Days)
- LNZA 1.8M
- SERA 687.0K
- Earning Date
- LNZA 08-07-2025
- SERA 08-06-2025
- Dividend Yield
- LNZA N/A
- SERA N/A
- EPS Growth
- LNZA N/A
- SERA N/A
- EPS
- LNZA N/A
- SERA N/A
- Revenue
- LNZA $48,831,000.00
- SERA $115,000.00
- Revenue This Year
- LNZA $58.17
- SERA $390.13
- Revenue Next Year
- LNZA $10.92
- SERA $440.54
- P/E Ratio
- LNZA N/A
- SERA N/A
- Revenue Growth
- LNZA N/A
- SERA N/A
- 52 Week Low
- LNZA $0.14
- SERA $1.37
- 52 Week High
- LNZA $2.74
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- LNZA 52.65
- SERA 58.21
- Support Level
- LNZA $0.27
- SERA $2.68
- Resistance Level
- LNZA $0.31
- SERA $3.10
- Average True Range (ATR)
- LNZA 0.03
- SERA 0.27
- MACD
- LNZA -0.00
- SERA 0.03
- Stochastic Oscillator
- LNZA 69.74
- SERA 45.99
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.